2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Serologic Tests, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Transfusion, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bleeding Disorders, Platelet Disorders, Thrombocytopenias, Immunology, Autoimmune Disorders, Infectious Diseases, Viral, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Pediatric, Neonatal, Young Adult
PAPER

4767 Long-term follow-up of eltrombopag plus low-dose cyclosporine as promising rescue therapy for patients with refractory immune thrombocytopenia: Tapering and sustained remission analysis

Meng Tian, Xiawan Yang2, Qi Liu3, Yaonan Hong4, Xinru Jia5, Tianye Zhou6, Minmin Zhang7, Jiale Zhang8, Tonglin Hu9, Yingying Shen10, Dijiong Wu, MD,PhD11
1 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
2 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
3 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
4 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
5 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
6 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
7 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
8 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
9 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
10 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
11 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China

Background: Eltrombopag (EPAG) , an oral thrombopoietin receptor agonist (TPO-RA) , has substantially improved outcomes in immune thrombocytopenia (ITP). However, a subset of patients develops resistance to EPAG monotherapy, manifesting as primary failure, relapse after initial response, or unstable platelet counts, representing a major unmet clinical challenge. Current rescue options, including switching TPO-RAs, fostamatinib, rituximab, splenectomy, or immunosuppressive therapies, are limited by delayed responses, variable efficacy, safety concerns, and substantial financial burden. Although our previous study demonstrated that EPAG combined with low-dose cyclosporine A (CsA) achieved a rapid response rate of 76.2% (16/21) in refractory ITP (Hong et al., Res Pract Thromb Haemost, 2023), the long-term efficacy, feasibility of treatment tapering, and potential for sustained response off treatment (SRoT) remain unclear. Herein, we evaluated long-term outcomes of EPAG plus CsA, focusing on real-world tapering practices, sustained remission, and safety.

Methods: This single-center retrospective study enrolled patinets with ITP who had insufficient, relapsed, or unstable responses to EPAG monotherapy and subsequently received EPAG plus low-dose CsA (with a trough concentration 75-120ng/mL before tapering). Complete response (CR) was defined as a platelet count ≥100×109/L and partial response (PR) as a platelet count between 30 and 100×109/L with at least a doubling of the pre-treatment count. Overall response (OR) included CR and PR. The primary endpoint was the proportion of responding patinets who achieved either treatment discontinuation or long-term maintenance therapy for ≥3 months. The secondary endpoint was the duration of sustained response (platelet counts ≥50×109/L) during maintenance or after treatment cessation. Adverse events were assessed according to CTCAE v6.0. Patients were followed from treatment initiation until the last visit or study end (30 June 2026), whichever occurred first.

Results: From July 2020 to June 2026, a total of 65 patients with ITP enrolled, with a median age of 48 years (range:13-85) and a female predominance (78.5%). The median interval from diagnosis to the initiation of EPAG combined with low-dose CsA was 24 months (range:2-360). Overall, 59 patinets (90.8%) achieved OR, including 50 (76.9%) with CR. The median time to initial response was 11 days (range:3-37). Among responders, 48 underwent treatment tapering. After a median follow-up of 26 months (range:8–66), 22/48 (45.8%) achieved the primary endpoint. Nine patients successfully discontinued treatment after a median duration of 18 months (range:7–26), with four maintaining sustained response off treatment at 12 months. The median daily doses of EPAG and CsA were 15.35 mg and 125.90 mg, respectively. Thirteen patients continued long-term low-dose EPAG plus CsA maintenance, with median daily doses of 12.5 mg and 100 mg, respectively. Among patients achieving the primary endpoint, 16 maintained platelet counts ≥100×109/L, and only two experienced relapse during follow-up. Treatment-emergent adverse events occurred in 20/65 patients (30.8%), mainly including headache, gingival hyperplasia, elevated creatinine, and nausea; most were manageable without treatment discontinuation, and only one patient discontinued therapy due to persistent creatinine elevation.

Conclusion: EPAG plus CsA demonstrated rapid and durable responses in EPAG-resistant ITP. Nearly half of tapered responders achieved treatment discontinuation or sustained low-dose maintenance, with a low relapse rate and manageable toxicity. These findings support EPAG plus CsA as a strategy to stabilize response and reduce long-term treatment burden. Large-scale prospective studies are warranted to confirm these results and clarify the mechanisms underlying rapid response.

Xiawan Yang: No relevant conflicts of interest to declare.